{"schema_version":"1","generated_at":"2026-11-06T00:59:01.769Z","data_as_of":null,"url":"https://www.findmykol.com/kol/angela-alistar","json_url":"https://www.findmykol.com/kol/angela-alistar/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"angela-alistar","name":"Angela Alistar","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Winston Salem","state":"NC","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1831349745","orcid":"0009-0009-0473-7513","openalex":"A5023523894"},"summary":"Angela Alistar is an Oncology physician. OpenAlex indexes 86 publications with 3,875 citations (h-index 15); ClinicalTrials.gov lists 3 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":86,"cited_by_count":3875,"h_index":15,"latest_activity_year":2026,"source":"works"},"trials":{"count":3,"shown":3,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05037149","title":"Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"Sirnaomics","source_url":"https://clinicaltrials.gov/study/NCT05037149","trial_url":"https://www.findmykol.com/trial/NCT05037149"},{"nct":"NCT03435289","title":"A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer","phase":"PHASE1","status":"UNKNOWN","role":"Overall official","sponsor":"Atlantic Health System","source_url":"https://clinicaltrials.gov/study/NCT03435289","trial_url":"https://www.findmykol.com/trial/NCT03435289"},{"nct":"NCT02566421","title":"Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery","phase":"NA","status":"TERMINATED","role":"Overall official","sponsor":"Wake Forest University Health Sciences","source_url":"https://clinicaltrials.gov/study/NCT02566421","trial_url":"https://www.findmykol.com/trial/NCT02566421"}],"source":"trials"},"payments":{"company_count":58,"program_years":{"first":2021,"last":null},"rows_total":160,"shown":3,"withheld":157,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":45119.44,"payment_count":35,"source_url":"https://openpaymentsdata.cms.gov/search?query=1831349745"},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2025,"amount_usd":27012.9,"payment_count":27,"source_url":"https://openpaymentsdata.cms.gov/search?query=1831349745"},{"payer":"Roche","program_year":2025,"amount_usd":23553.25,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1831349745"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1831349745","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer","year":2026,"journal":"Cancer","source_url":"https://doi.org/10.1002/cncr.70343","status":"verified"},{"title":"Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study","year":2026,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyag023","status":"verified"},{"title":"Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies","year":2025,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2025-011572","status":"verified"},{"title":"Abstract B094: Ketogenic Diet Modulates Gut Microbiome Composition and Enhances Treatment Response in Patients with Advanced Pancreatic Cancer: A Phase II Study","year":2025,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.pancreatic25-b094","status":"verified"},{"title":"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.02659","status":"verified"}],"source":"works"},"contact":{"address_1":"MEDICAL CENTER BLVD","city":"Winston Salem","state":"NC","zip":"271570001","phone":"336-713-5445","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1831349745","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":157,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2016-12-16","collected_at":"2026-11-05T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}